Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupFRA:6MD 91 EV-to-FCF is 339.97 as of Jul. 17, 2026, which is 205% above its 10-year median of 111.39. GuruFocus rates FRA:6MD with a GF Score™ of 91/100 and a GF Value™ of €180.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Medacta Group ranks worse than 95.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medacta Group's Enterprise Value is €3,248.0 Mil.
Medacta Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €9.6 Mil. Therefore, Medacta Group's EV-to-FCF for today is 339.97.
The historical rank and industry rank for Medacta Group's EV-to-FCF or its related term are showing as below:
FRA:6MD'
s EV-to-FCF Range Over the Past 10 Years
Min: -5098.95 Med: 111.39 Max: 1435.01
Current: 334.41
During the past 11 years, the highest EV-to-FCF of Medacta Group was 1435.01. The lowest was -5098.95. And the median was 111.39.
FRA:6MD's EV-to-FCF is ranked worse than 95.17% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.635
vs FRA:6MD: 334.41
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medacta Group's PE Ratio (TTM) for today is calculated as:
Medacta Group's share price for today is €146.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medacta Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €4.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medacta Group EV-to-FCF Related Terms
Medacta Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Medacta Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medacta Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Medacta Group's EV-to-FCF falls into.
Medacta Group's current Enterprise Value is €3,248.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medacta Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €9.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group (FRA:6MD) has a EV-to-FCF of 339.97 as of Jul. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medacta Group and its competitors. This is 205% above median its historical median of 111.39. According to the industry distribution chart, Medacta Group ranks #394 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 95.2%.
Is Medacta Group's EV-to-FCF too high?
Medacta Group's current EV-to-FCF of 339.97 is 205% above median its 10-year median of 111.39. The Medical Devices & Instruments industry median EV-to-FCF is 23.64. Medacta Group's value of 339.97 is 1338.4% above this industry median. Based on the distribution chart, Medacta Group ranks #394 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medacta Group has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #394 out of 414 companies for EV-to-FCF. This places Medacta Group in the lower half of its industry. The industry median EV-to-FCF is 23.64. Medacta Group's value of 339.97 is 1338.4% above this benchmark. While the company's 10-year median is 111.39 vs. the industry median of 23.64, Medacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.64, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current EV-to-FCF of 339.97 is 1338.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current EV-to-FCF is 339.97, which is 205% above median its own 10-year median of 111.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (FRA:6MD) is currently considered Modestly Undervalued. The stock's GF Value™ is €180.03, compared to a current price of €146.00 — trading 18.9% below its estimated fair value. The current EV-to-FCF is 339.97, which is 205% above median its 10-year median of 111.39 and 1338.4% above the Medical Devices & Instruments industry median of 23.64. Medacta Group's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Medacta Group (FRA:6MD), the current EV-to-FCF is 339.97 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (FRA:6MD) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of €146.00 is trading 18.9% below its estimated GF Value™ of €180.03.
GuruFocus considers Medacta Group to be Modestly Undervalued.
Key valuation signals for FRA:6MD:
EV-to-FCF: 339.97 (205% above median its 10-year median of 111.39)
GF Value™: €180.03 vs. price of €146.00 (18.9% below fair value)
Industry Position: 1338.4% above the Medical Devices & Instruments median (#394 of 414)
No single metric tells the full story. See the FRA:6MD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score
Get the complete analysis for FRA:6MD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6MD has been successfully added to your 
